Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.52 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15627215 | 1.00 | SLC22A6 (0.52) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL15627217 | 1.00 | SLC22A6 (0.52) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL15627216 | 1.00 | SLC22A6 (0.52) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL4541049 | 1.00 | SLC22A6 (0.52) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL6477452 | 1.00 | SLC22A6 (0.52) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL9730926 | 0.98 | SLC22A6 (0.50) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL1961185 | 0.98 | SLC22A6 (0.50) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL30645407 | 0.98 | SLC22A6 (0.50) | SLC22A6GABRR1LMNAMAPTSLC6A2 | |
| SCHEMBL22472213 | 0.84 | SLC22A6 (0.38) | SLC22A6GABRR1LMNAMAPTCYP2D6 | |
| SCHEMBL22472215 | 0.84 | SLC22A6 (0.38) | SLC22A6GABRR1LMNAMAPTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117417677-A | Water-based moisture-cured cold zinc acid and alkali resistant anticorrosive paint and application thereof | 石家庄市鱼莎电力物资工程有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-114958134-A | Water-based epoxy moisture-curing acid-and-alkali-resistant coating and preparation method thereof | 石家庄市鱼莎电力物资工程有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-114076802-A | Analysis method for quantitatively detecting nitrogen and oxygen impurities in pitavastatin calcium | 徐州万邦金桥制药有限公司 | 2022-02-22 | — | — | CN | claimed |
| WO-2020197042-A1 | METHOD FOR PREPARING ROSUVASTATIN CALCIUM SALT | (주)헥사파마텍 | 2020-10-01 | — | — | WO | claimed |
| US-7692018-B2 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-06 | — | — | US | claimed |
| EP-1667974-B1 | PROCESS FOR PRODUCING HIGH PURITY 3,5-DIHYDROXY-6-HEPTENOIC ACID DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2009-07-29 | — | — | EP | claimed |
| EP-1968593-A2 | PHARMACEUTICAL COMPOSITION COMPRISING (E)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-[METHYL(METHYLSULFONYL)AMINO]PYRIMIDIN-5-YL-(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID | LEK Pharmaceuticals D.D. (SI) | 2008-09-17 | — | — | EP | claimed |
| WO-2007071357-A2 | PHARMACEUTICAL COMPOSITION COMPRISING (E) -7- [4- (4-FLUOROPHENYL) -6-ISOPROPYL-2- [METHYL (METHYLSULFONYL) AMINO] PYRIMIDIN-5 -YL- (3R, 5S) -3, 5-DIHYDR0XYHEPT-6-EN0IC ACID | LEK PHARMACEUTICALS D.D. (SI) | 2007-06-28 | — | — | WO | claimed |
| JP-2007507417-A | — | — | 2007-03-29 | — | — | JP | claimed |
| US-20060229451-A1 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-12 | — | — | US | claimed |
| EP-1667974-A1 | PROCESS FOR PRODUCING HIGH PURITY 3,5-DIHYDROXY-6-HEPTENOIC ACID DERIVATIVE | Nissan Chemical Industries, Ltd. (JP) | 2006-06-14 | — | — | EP | claimed |
| WO-2005033083-A1 | PROCESS FOR PRODUCING HIGH PURITY 3,5-DIHYDROXY-6-HEPTENOIC ACID DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | WO | claimed |
| WO-2025090648-A1 | METHODS AND COMPOSITIONS FOR INHIBITING METASTASIS OF SOLID TUMORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | ENDOPERFUSION SOLUTIONS, LLC | 2024-06-13 | — | — | US | disclosed |
| CN-117417677-A | Water-based moisture-cured cold zinc acid and alkali resistant anticorrosive paint and application thereof | 石家庄市鱼莎电力物资工程有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117050012-A | Preparation method of 3, 5-dihydroxy-6-sodium heptenoate | 江苏天晟药业股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-4808621-A | Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis | WARNER-LAMBERT COMPANY (US) | 1989-02-28 | — | — | US | disclosed |
| US-4751229-A | Treating fungal infections with substituted-(6-(tetrahydro-4-hydroxy-2-oxo-2H-pyran-2-yl)ethyl)- or ethenyl)pyrazoles | WARNER-LAMBERT COMPANY (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0252476-A2 | Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof | WARNER-LAMBERT COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| WO-1984002903-A1 | MEVALONOLACTONE ANALOGS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1984-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189221-A1 | METHODS AND FORMULATIONS FOR TREATING VASCULAR DISEASE | LIPG, APOB, LIPA | SLC22A6 597/4885GABRR1 2207/4885LMNA 1059/4885 |
| US-20060229451-A1 | Process for producing high purity 3,5-dihydroxy-6-heptenoic acid derivative | ADH1A, ADH1C, DHCR7 | SLC22A6 3327/4885GABRR1 1484/4885LMNA 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.